Finasteride NDC 0093-7355

NDC codes

FDA NDC Directory

Product NDC (as listed)0093-7355Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00093-7355Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
0093-7355-05	00093735505	500 TABLET, FILM COATED in 1 BOTTLE (0093-7355-05)Marketed from Mar 14, 2008
0093-7355-56	00093735556	30 TABLET, FILM COATED in 1 BOTTLE (0093-7355-56)Marketed from Dec 15, 2006
0093-7355-98	00093735598	90 TABLET, FILM COATED in 1 BOTTLE (0093-7355-98)Marketed from Feb 22, 2007

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Finasteride
Generic name (nonproprietary): finasteride
Active ingredients: Finasteride — 5 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Teva Pharmaceuticals USA, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 076511
Marketing start: Dec 15, 2006
Marketing end: Sep 30, 2026
Other FDA classes: 5-alpha Reductase Inhibitors (Mechanism)
Identifiers: Product ID 0093-7355_0e34d8a4-1d1f-4466-8f46-f8dbf1ef9b34SPL ID 0e34d8a4-1d1f-4466-8f46-f8dbf1ef9b34SPL set ID 77589cc3-c440-4695-800c-82a0e5128a6cRxCUI 310346UNII 57GNO57U7GUPC 0300937355564
Pharmacologic class: 5-alpha Reductase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400093735505 followed by a unit qualifier and the quantity

Package 00093-7355-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 18, 2026.

Indications (excerpt from the label)

Finasteride, is a 5α-reductase inhibitor, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to ( 1.1 ): Improve symptoms Reduce the risk of acute urinary retention Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. Finasteride administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed ≥4 point increase in American Urological Association (AUA) symptom score) ( 1.2 ). Limitations of Use : Finasteride is not approved for the prevention of prostate cancer ( 1.3 ). 1.1 Monotherapy Finasteride …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)